Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Can-Fite BioPharma ( (CANF) ).
On March 4, 2026, Can-Fite BioPharma entered a definitive inducement agreement with a warrant holder for the immediate cash exercise of outstanding warrants to purchase 795,869 ADSs, cutting the exercise price from $9.34 to $5.00 per ADS. The transaction, expected to close around March 5, 2026, should generate about $4.0 million in gross proceeds before fees, which the company plans to deploy toward research and development, clinical trials, and general corporate purposes.
In return for the repriced exercise, Can-Fite will issue new unregistered warrants to purchase up to 1,591,738 ADSs at $5.00 per ADS, exercisable for two years after the effectiveness of a planned resale registration statement. The deal, arranged with H.C. Wainwright as exclusive placement agent, provides near-term non-dilutive cash from existing warrants while layering in future potential equity issuance, giving the company incremental funding flexibility as it advances multiple late-stage clinical programs.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing proprietary small-molecule drugs targeting cancer, liver, and inflammatory diseases. Its lead candidate Piclidenoson is in a pivotal Phase III trial for psoriasis, while Namodenoson is in Phase III for hepatocellular carcinoma, Phase IIb for MASH, and Phase IIa for pancreatic cancer, with orphan and Fast Track designations in HCC.
Average Trading Volume: 877,608
Technical Sentiment Signal: Sell
Current Market Cap: $12.63M
Learn more about CANF stock on TipRanks’ Stock Analysis page.